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Summary 
Objective:  Both the local and systemic inflammatory responses appear to predict outcome in 
patients undergoing nephrectomy for renal cell carcinoma.  To date almost all studies have 
examined such factors in isolation.  The aim of the present study was therefore to examine the 
relationship between the systemic inflammatory response (C-reactive protein), tumour 
interleukin-6 receptor and COX-2 expression, tumour T-lymphocytic (CD4+, CD8+) 
infiltration and cancer survival in patients undergoing resection for renal cancer. 
Patients and Methods:  Sixty patients undergoing nephrectomy for localised renal cancer 
were studied.  Pre-operative circulating C-reactive protein concentrations were measured and 
tumour interleukin-6 receptor and cyclo-oxygenase-2 expression, tumour CD4+ and CD8+ T-
lymphocytes were assessed using immunohistochemical analysis. 
Results: Median follow up was 78 months with 14 patients relapsing from their disease and 9 
cancer specific deaths.  On univariate and multivariate survival analysis tumour stage and 
grade and C-reactive protein were identified as significant factors associated with relapse-free 
and cancer specific survival.  There was a significant direct relationship between Fuhrman 
grade and CD4+ T-lymphocytic infiltrate (p<0.05).  An increase in tumour expression of 
interleukin-6 receptor was weakly associated with an increase in tumour CD8+ T-
lymphocytic infiltration (p=0.057).  An increase in tumour CD4+ T-lymphocytic infiltration 
was associated with an increase in CD8+ T-lymphocytic infiltration (p<0.01).   
Conclusions: In summary, the results of the present study would suggest that tumour-based 
factors such as interleukin-6 receptor and COX-2 expression or T-lymphocytic subset 
infiltration are subordinate to systemic factors such as C-reactive protein in determining 
survival in patients with localised renal cancer.  
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Introduction 
Renal cell cancer, although the 12th most common cause of cancer death is one of the 
most lethal urological cancers.  Each year in the UK, there are approximately 3,500 new cases 
and approximately 30% of these patients present with metastases.  Overall survival is poor; 
even in those who undergo potentially curative resection, only approximately half survive 5 
years (Cancerstats, www.cancerresearchuk.org).  
It is increasingly recognised that cancer progression is dependent on a complex 
interaction of the tumour and host inflammatory response [1,2,3].  Indeed, the systemic 
inflammatory response, as evidenced by elevated circulating concentrations of C-reactive 
protein, has been shown to be independently associated with poorer survival in patients with 
advanced malignancies [4,5,6] including renal cancer [7,8,9,10,11]. 
There is also evidence that C-reactive protein has independent prognostic value in a 
variety of primary operable cancers [12,13,14,15].  Recently, it has been reported that an 
elevated pre-operative C-reactive protein is associated with poor cancer specific survival in 
patients with operable renal cancer independent of tumour stage and grade [16,17].   
The basis of the independent relationship between an elevated pre-operative C-
reactive protein concentration and poor cancer specific survival in cancer is not clear.  There 
are a number of possible explanations.  Firstly, that an elevated C-reactive protein identifies 
tumours capable of producing significant amounts of pro-inflammatory cytokines, in 
particular interleukin-6 [18,19], and therefore with the potential for more rapid growth of 
tumour cells [20,21].  Alternatively, C-reactive protein could directly impair immune function 
[22,23,24] allowing unrestrained tumour growth and dissemination.  
Precise localisation of pro-inflammatory cytokines such as interleukin-6 to tumour 
cells or inflammatory cells within the tumour, particularly in paraffin embedded tissues, 
remains problematic [24].  However, interleukin-6 activity has been assessed by staining for 
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interleukin-6 receptor expression in a variety of solid tumours, including renal cancer [25] and 
infiltration of tumours with T- lymphocytes has been reliably demonstrated in a variety of 
solid tumours, including renal cancer [26,27].   
The molecular basis of the increased production of interleukin-6 and other pro-
inflammatory cytokines by the renal tumour remains to be defined.  However, central to the 
local inflammatory response is cyclooxygenase-2 (COX-2) and increased expression has been 
shown to be associated with poor survival in a number of common solid tumours [28,29].  
COX-2 is the rate limiting enzyme in the synthesis of prostaglandin E2 (PGE2) which is 
known to stimulate proliferation and inhibit apoptosis.  PGE2 is also recognised to induce 
interleukin-6 [30] and NSAIDs have been shown to reduce interleukin-6 concentrations in 
cancer patients [31,32] or animal cancer models [33].   
In normal tissues COX-2 is usually absent, however, the kidney is unusual in that 
there is expression of COX-2 in physiological health [34].  Few studies have examined the 
role of COX-2 in renal cancer.  There is conflicting evidence as to whether increased COX-2 
expression is associated with poor survival in renal cancer [35,36].   
Recently, there have been comparisons between the local and systemic inflammatory 
responses and survival in colorectal [24] and bladder [14] cancer.  However, to our 
knowledge such comparison has not been carried out in renal cancer.  The aim of the present 
study was therefore to examine the relationship between the systemic inflammatory response 
(C-reactive protein), tumour interleukin-6 receptor and COX-2 expression, tumour T-
lymphocytic (CD4+, CD8+) infiltration and cancer survival in patients undergoing resection 
for localised renal cell cancer. 
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Patients and Methods 
Patients diagnosed with renal clear cell cancer, who underwent potentially curative 
resection for localized disease between November 1997 and April 2004 in the West of 
Scotland, were included in the study.   
Patients were staged clinically on the basis of surgical findings and pre-operative 
computed tomography of chest abdomen and pelvis and  pathologically according to the 1997 
UICC TNM classification of renal tumours [37].  At this time no patient showed clinical 
evidence of infection or other inflammatory conditions.   
Tumours were graded by experienced pathologists according to criteria set out by 
Fuhrman and coworkers [38].  Also, routine laboratory measurement of patient’s serum for C-
reactive protein concentration prior to surgery was performed. The limit of detection of the 
assay was a C-reactive protein concentration lower than 6mg/l.  The coefficient of variation, 
over the range of measurement, was less than 5% as established by routine quality control 
procedures.  C-reactive protein measurement of greater than 10mg/l was considered to 
indicate the presence of a systemic inflammatory response [4].  
The Research Ethics Committee of North Glasgow NHS Trust approved the study. 
Immunohistochemistry 
Blocks from the primary tumour were fixed in 10% buffered formalin and embedded 
in paraffin wax.  One representative block of tumour was selected for each patient.  Serial 
individual sections (4 µm) were cut and mounted on slides coated with 
aminopropyltriethoxysilane for the immunohistochemistry of interleukin-6 receptor, CD4+ 
and CD8+ T-lymphocytes and COX-2 expression. 
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Interleukin-6 receptor 
 Slides were dewaxed in xylene and rehydrated using graded alcohols.  Antigen 
retrieval for IL-6 receptor was carried out by incubating in 10mM citrate buffer (Epitope 
retrieval solution x 10, Dako, Cambridgeshire, UK) in a calibrated water bath at 96oC for 20 
minutes.  Slides were then immersed in 0.3% hydrogen peroxide for 20 minutes to block 
endogenous peroxidases.  The primary antibody for interleukin-6 receptor was rabbit 
polyclonal (Santa Cruz Biotechnology Inc, USA).  Sections were immunostained using a 
streptavidin biotin technique (Dako, Cambridgeshire, UK).  Sections were counterstained 
with haematoxylin, dehydrated, cleared and mounted. 
 
CD4+ and CD8+ T-lymphocytes 
Sections were immunostained using the peroxidase-based Envision technique (Dako, 
Cambridgeshire, UK) as described previously [27].  The primary antibody for CD4 was 
mouse monoclonal (Vector, Peterborough, UK) and that for CD8 was mouse monoclonal 
(Dako, Cambridgeshire, UK). 
 
COX-2 
Sections were immunostained using the biotinylated/streptavidin peroxidase complex 
technique (Dako, Cambridgeshire, UK) as previously described (Edwards et al, 2004).  The 
primary antibody was human monoclonal antibody (Cayman Chemical Co., Annbor, 
Michigan, USA).   
 
Morphometry 
Quantitative analysis of the lymphoid infiltrate was performed using point counting 
[27] with a random sampling technique. With this method, the volume occupied by any given 
 6
component (volume density) is expressed as a percentage of the total volume of the tissue. A 
100-point ocular grid was used at x400 magnification and 30 fields were counted per case for 
CD4+ and CD8+ immunopositive cells.  Only fields within the tumour (including cancer cell 
nests and surrounding tissue stroma) were counted. Any normal tissue on the slide was 
excluded from the analysis. 
COX-2 and IL-6 receptor expression were assessed as previously described [39].  
Percentage tumour cells stained were scored as 0-20% = 1, 21-50% = 2 and 51-100% = 3.  
This score is then multiplied by the predominant intensity of staining; 0 = no stain, 1 = weak 
stain, 2 = moderate stain and 3 = strong staining gaining a final score ranging from 0 – 9.  For 
analysis, scores were grouped in tertiles. 
Slides were examined by independent observers (GWAL, PAM and SR) blind to the 
clinical outcome of the patient. 
 
Statistics 
For the purpose of analysis, the tumour interleukin-6 receptor, CD4+ and CD8+ T-
lymphocyte counts and COX-2 expression were grouped by tertiles.  The relationships 
between these and other variables were analyzed using the Mantel–Haenszel (X2) test for 
trend and Spearman’s rank correlation as appropriate. 
Survival analysis was performed using the Cox proportional hazard model.  
Multivariate survival analysis was performed using stepwise backward procedure to derive a 
final model of the variables that had a significant independent relationship with survival.  To 
remove a variable from the model, the corresponding P-value had to be greater than 0.10.  
Deaths up to the end of April 2007 were included in the analysis.  Analysis was performed 
using SPSS software (SPSS Inc., Chicago, IL, USA). 
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Results 
 The characteristics and cancer specific survival of patients who underwent a 
potentially curative resection for renal cancer (n= 60) are shown in Table 1.  The majority of 
patients were over 60 years of age, were male, were TNM stage I/ II and had Fuhrman grade 
I-II disease.  In the 23 patients who had TNM stage III disease this was based on T stage, no 
patients had involved lymph nodes.  Approximately one third of patients had an elevated C-
reactive protein concentration (>10mg/l).   
The minimum follow-up was 37 months; the median follow-up of the survivors was 
78 months.  During this period, 14 patients relapsed and 9 died of their cancer; a further 8 
patients died of intercurrent disease.  On univariate survival analysis, age (p<0.10), TNM 
stage (p<0.05), Fuhrman grade (p<0.01) and C-reactive protein (p<0.05) were significant 
predictors of relapse-free survival.  On multivariate analysis with age, TNM stage, Fuhrman 
grade, and C-reactive protein entered as covariates, age (HR 0.26, 95%CI 0.09-0.75, 
p=0.0175, TNM stage (HR 2.11, 95%CI 1.05-4.22, p=0.0351) and C-reactive protein (HR 
2.66, 95% CI 0.88–8.03, p=0.0838) were independent predictors of relapse-free survival.   
On univariate survival analysis, TNM stage (p<0.01), Fuhrman grade (p<0.01), COX-
2 expression (p<0.05) and C-reactive protein (p<0.05) were significant predictors of cancer 
specific survival.  On multivariate analysis with TNM stage, Fuhrman grade, COX-2 
expression and C-reactive protein entered as covariates, TNM stage (HR 5.98, 95%CI 1.25-
28.59, p=0.0250) and C-reactive protein (HR 3.40, 95% CI 0.81–14.38, p=0.0950) were 
independent predictors of cancer specific survival.   
The inter-relationships between the clinicopathological characteristics in patients 
undergoing resection for renal cancer are shown in Table 2.  An increase in Fuhrman grade 
was associated with increased tumour CD4+ T-lymphocytic infiltration (p<0.05).  An increase 
in tumour expression of interleukin-6 receptor was weakly associated with an increase in 
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tumour CD8+ T-lymphocytic infiltration (p=0.057).  An increase in tumour CD4+ T-
lymphocytic infiltration was associated with an increase in CD8+ T-lymphocytic infiltration 
(p<0.01).  The Spearman rank correlation between tumour CD4+ and CD8+ T-lymphocytic 
infiltration was 0.47 (p<0.001). 
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Discussion 
In the present study, in addition to tumour stage and grade, the presence of a systemic 
(C-reactive protein) but not a local (tumour IL-6 receptor, COX-2 expression and CD4+/ 
CD8+ T lymphocytic infiltrate) inflammatory response was associated with poor relapse free 
and cancer specific survival in patients undergoing potentially curative resection for renal 
cancer.  These results confirm the importance of circulating concentrations of C-reactive 
protein in the staging and prognosis of patients with localised renal cancer [16,17,40,41] and 
suggest that that tumour-based inflammation factors such as IL-6 receptor, COX-2 expression 
or T-lymphocytic infiltration are subordinate to systemic factors such as C-reactive protein in 
determining cancer outcome in these patients.  
C-reactive protein concentrations above the threshold used in the present study (>10 
mg/ l) are rare (<5%) in the general elderly population in the West of Scotland [42] and 
elevated circulating C-reactive protein concentrations are primarily determined by circulating 
IL-6 [43].  IL-6 is expressed in the majority of renal cancers and has been proposed as an 
autocrine growth factor [7,44,45].  Furthermore, circulating IL-6 has been shown to be 
associated with increased tumour grade, volume and metastasis in patients with renal cancer 
[46].  However, in the present study tumour cell expression of interleukin-6 receptor, a 
surrogate marker for interleukin-6, was not significantly associated with circulating 
concentrations of C-reactive protein.  This would suggest that the main source of interleukin-6 
responsible for an elevated C-reactive protein, in patients with localised renal cancer, was 
unlikely to be the tumour itself.  However, a wide range of cell types are known to produce 
interleukin-6 and therefore the main source remains to be established [47].  
In the present study, in contrast to previous studies [27,48] tumour CD4+ lymphocytic 
infiltrate was not associated with cancer specific survival.  However, previous studies 
included patients, in terms of tumour stage and grade, with more advanced disease and 
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therefore the present results reflect early changes in the tumour inflammatory infiltrate.  
Nevertheless, the observation that, in the present study, tumour CD4+ lymphocytic infiltrate 
was directly associated with tumour grade and would be consistent with an increase in CD4+ 
T-lymphocytic infiltration being an early host inflammatory response in patients with renal 
cancer. 
In the only other reported study, Costes and coworkers [25] reported a significant 
association between the presence of the IL-6 receptor in renal tumours and stage and grade.  
Furthermore, they reported that those patients with positive staining of IL-6R had poorer 
survival.  In the present study tumour IL-6 receptor was not significantly associated with 
stage, grade or survival.  Costes and coworkers [25] in their study examined 38 patients with 
mean follow-up 14 months compared with 60 patients and a mean follow-up of approximately 
6 years in the present study.  However, since both studies used a semi-quantitative assessment 
of IL-6 receptor further work is required to establish whether or not tumour expression of IL-6 
receptor has prognostic value in patients with renal cancer. 
Few studies have examined the expression of COX-2 in renal cancer.  Some studies 
have suggested that it is increased with tumour stage and grade [35,36,49].  In contrast, 
consistent with other workers [50] we observed no such relationship.  Also, consistent with 
previous studies [35,36,50] the present study showed little prognostic value for tumour COX-
2 expression.  
The results of the present study are consistent with the superior prognostic value of C-
reactive protein compared with tumour T-lymphocytic infiltration and COX-2 expression in 
primary operable colorectal and bladder cancer [24,14].  One possible explanation is that C-
reactive protein can be measured with greater accuracy and precision than tumour-based 
factors.  Alternatively, it may be that C-reactive protein plays a more pivotal role in the 
tumour–host relationship.  C-reactive protein is recognised to be not only an activator of 
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innate immunity but also a modulator of adaptive immunity [23] and its elevation appears to 
be a precursor to tumour dissemination and progressive involuntary loss of weight and lean 
tissue [51] which are key factors in determining cancer survival.  Also, it is of interest that 
Jabs and co-workers [52] reported that tumour expression of C-reactive protein was directly 
associated with circulating concentration.  It would therefore appear that tumour derived C-
reactive protein concentration may make a contribution to circulating systemic levels.  
Therefore, the use of C-reactive protein, rather than tumour tissue based factors, in addition to 
tumour stage and grade, to more accurately stratify patients with localised renal cancer has 
much to commend it, particularly since it is well standardised worldwide.   
In summary, the results of the present study would suggest that tumour-based factors 
such as interleukin-6 receptor and COX-2 expression or T-lymphocytic subset infiltration are 
subordinate to systemic factors such as C-reactive protein in determining survival in patients 
with localised renal cancer.  
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Table 1.  Clinicopathological characteristics and survival in patients undergoing potentially curative resection for renal cancer: univariate 
analysis. 
  Relapse free survival  Cancer specific survival  
   Patients Hazard ratio 
n= 60 (95%CI) 
p-value Hazard ratio
(95%CI) 
p-value 
Age group (<60/ >60 yrs) 24/ 36 0.34 (0.11-1.01) 0.0530 0.36 (0.09-1.44) 0.1498 
Sex (male/ female) 37/ 23 0.67 (0.21-2.13) 0.4943 0.80 (0.20-3.20) 0.7511 
TNM stage (I/ II/ III) 27/10/ 23 2.12 (1.11-4.03) 0.0227 5.36 (1.55-18.47) 0.0079 
Fuhrman grade (I/ II/ III/ IV) 16/ 25/ 12/ 6 2.46 (1.39-4.32) 0.0019 3.43 (1.64-7.17) 0.0010 
IL-6 receptor (tertiles 1, 2, 3) 140 (0-300)* 1.03 (0.54-1.99) 0.9207 1.24 (0.52-2.98) 0.6148 
COX-2 (tertiles 1, 2, 3) 100 (0-200)* 1.42 (0.71-2.82) 0.3229 2.55 (1.02-6.37) 0.0455 
T-lymphocytes 
(% tumour volume) 
    CD4+ (tertiles 1, 2, 3) 
    CD8+ (tertiles 1, 2, 3) 
 
 
0.40 (0.01-1.80)* 
0.88 (0.01-7.07)* 
 
 
1.70 (0.84-3.45) 
0.73 (0.39-1.39) 
 
 
0.1397 
0.3143 
 
 
2.11 (0.80-5.56) 
0.57 (0.25-1.30) 
 
 
0.1294 
0.1798 
      
C-reactive protein 
(<10/ >10 mg/l) 
 
38/ 22 
 
2.89 (1.00-8.39) 
 
0.0416 
 
4.83 (1.20-19.48) 
 
0.0269 
*median (range) 
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Table 2.  The inter-relationships between the clinicopathological characteristics in patients undergoing potentially curative resection for renal 
cancer. 
 Fuhrman grade  IL-6 receptor 
(I/ II/ III/ IV) (tertiles 1, 2, 3) 
COX-2  
(tertiles 1, 2, 3) 
CD4+  
(tertiles 1, 2, 3) 
CD8+  
(tertiles 1, 2, 3) 
C-reactive protein 
(<10/ >10 mg/l) 
       
        
  
      
  
p-value p-value p-value p-value p-value p-value
TNM stage (I/ II/ III) 0.112 0.184 0.210 0.586 0.731 0.312
Fuhrman grade 
(I/ II/ III/ IV) 0.274 
 
0.334 
 
0.033 
 
0.750 
 
0.135 
IL-6 receptor 
(tertiles 1, 2, 3) 
0.097 0.841 0.057 0.101
COX-2 (tertiles 1, 2, 3)    0.278 0.100 0.754 
T-lymphocytes 
(% tumour volume) 
    CD4+ (tertiles 1, 2, 3) 
 
 
 
 
 
 
 
 
 
0.002 
 
 
0.732 
    CD8+ (tertiles 1, 2, 3)      0.515 
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